Company intelligence / Profile preview
Anhui HygeianCells BioMedical
Anhui Sheng, Chinahygeiancells.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Anhui HygeianCells BioMedical is a private Chinese biotech company founded in 2019, developing at least one clinical-stage asset (EE-001) for heart failure currently in early Phase 1 trials as of April 2025. The company also holds patents related to therapies for macrophage-mediated diseases, enteritis, and intestinal cancer. No detailed clinical results are publicly available yet.[1][2][4]
- Therapeutic areas
- ImmunologyGastroenterologyCardiovascular
- Modalities
- Unknown (insufficient public data to specify; likely Small molecule or Biologic based on typical early-stage biotech focus)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major partnerships disclosed as of April 2025.[4]
Beyond the preview
Go deeper on Anhui HygeianCells BioMedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anhui HygeianCells BioMedical.